Most Clicked StoriesMore >


Mylan's pricing strategy is common in the drug industry

PCMA SmartBrief | Aug 25, 2016

Mylan has increased the pace of its price hikes for EpiPen autoinjectors since 2012, when the company agreed to allow a generic competitor into the market in 2015. Raising prices ahead of looming generic competition is common in the drug industry, Express Scripts spokesman David Whitrap said. The New York Times (free-article access for SmartBrief readers) (08/24)


How drugmakers continue to reap profits after patents expire

PCMA SmartBrief | Aug 22, 2016

Video: PCMA on CNBC defending the PBM industry

PCMA SmartBrief | Aug 26, 2016

Senator asks Mylan to justify EpiPen price hike

PCMA SmartBrief | Aug 23, 2016

Mylan is free to cut prices

PCMA SmartBrief | Aug 26, 2016

Cost of EpiPen increases 400%

PCMA SmartBrief | Aug 22, 2016

Patients with diabetes struggle to afford insulin

PCMA SmartBrief | Aug 25, 2016

Limiting patents might restrain drug prices

PCMA SmartBrief | Aug 24, 2016

CAR-T therapies kill cancer but might kill the patient, too

PCMA SmartBrief | Aug 23, 2016

Dialysis companies under CMS scrutiny over 3rd-party premium payments

PCMA SmartBrief | Aug 23, 2016


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more